Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Raine

Showing results (11-20 of 107) with videos related to

Pageof 11
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|December 3, 2004
Can helminth antigens be exploited therapeutically to downregulate pathological Th1 responses?Tim Raine, Paola Zaccone, David W Dunne, et al.
Acta Paediatrica (Oslo, Norway : 1992)|May 5, 2017
Probiotics for the prevention of necrotising enterocolitis in very low-birth-weight infants: a meta-analysis and systematic reviewJohn P Thomas, Tim Raine, Sanath Reddy, et al.
Annals of Gastroenterology|January 3, 2017
Diagnosis and treatment of anemia in patients with inflammatory bowel diseaseVictoria Mücke, Marcus M Mücke, Tim Raine, et al.
Infection and Immunity|October 18, 2006
Inhibition of autoimmune type 1 diabetes by gastrointestinal helminth infectionKarin A Saunders, Tim Raine, Anne Cooke, et al.
European Journal of Immunology|September 18, 2004
Salmonella typhimurium infection halts development of type 1 diabetes in NOD micePaola Zaccone, Tim Raine, Stéphane Sidobre, et al.
Therapeutic Advances in Gastroenterology|April 20, 2026
Patterns of conventional therapy use and advanced therapy initiation drivers in inflammatory bowel diseaseTim Raine, Christian Agboton, Alex Geddes, et al.
Gut|May 7, 2014
Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immune-mediated diseaseTim Raine, Jimmy Z Liu, Carl A Anderson, et al.
Frontline Gastroenterology|April 28, 2021
Steroid use and misuse: a key performance indicator in the management of IBDJonathan Blackwell, Christian Selinger, Tim Raine, et al.
Alimentary Pharmacology & Therapeutics|May 25, 2022
Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids studyKonstantina Rosiou, Jenelyn Carbonell, Vivien Dolby, et al.
Therapeutic Advances in Musculoskeletal Disease|March 31, 2021
Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature reviewJobie Evans, Mark Sapsford, Scott McDonald, et al.
Pageof 11

Showing results (11-20 of 107) with videos related to

Sort By:
Pageof 11
Current Opinion in Investigational Drugs (London, England : 2000)|December 3, 2004
Can helminth antigens be exploited therapeutically to downregulate pathological Th1 responses?Tim Raine, Paola Zaccone, David W Dunne, et al.
Acta Paediatrica (Oslo, Norway : 1992)|May 5, 2017
Probiotics for the prevention of necrotising enterocolitis in very low-birth-weight infants: a meta-analysis and systematic reviewJohn P Thomas, Tim Raine, Sanath Reddy, et al.
Annals of Gastroenterology|January 3, 2017
Diagnosis and treatment of anemia in patients with inflammatory bowel diseaseVictoria Mücke, Marcus M Mücke, Tim Raine, et al.
Infection and Immunity|October 18, 2006
Inhibition of autoimmune type 1 diabetes by gastrointestinal helminth infectionKarin A Saunders, Tim Raine, Anne Cooke, et al.
European Journal of Immunology|September 18, 2004
Salmonella typhimurium infection halts development of type 1 diabetes in NOD micePaola Zaccone, Tim Raine, Stéphane Sidobre, et al.
Therapeutic Advances in Gastroenterology|April 20, 2026
Patterns of conventional therapy use and advanced therapy initiation drivers in inflammatory bowel diseaseTim Raine, Christian Agboton, Alex Geddes, et al.
Gut|May 7, 2014
Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immune-mediated diseaseTim Raine, Jimmy Z Liu, Carl A Anderson, et al.
Frontline Gastroenterology|April 28, 2021
Steroid use and misuse: a key performance indicator in the management of IBDJonathan Blackwell, Christian Selinger, Tim Raine, et al.
Alimentary Pharmacology & Therapeutics|May 25, 2022
Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids studyKonstantina Rosiou, Jenelyn Carbonell, Vivien Dolby, et al.
Therapeutic Advances in Musculoskeletal Disease|March 31, 2021
Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature reviewJobie Evans, Mark Sapsford, Scott McDonald, et al.
Pageof 11